Compared to Estimates, Docebo (DCBO) Q3 Earnings: A Look at Key Metrics

For the quarter ended September 2025, Docebo Inc. (DCBO) reported revenue of $61.62 million, up 11.2% over the same period last year. EPS came in at $0.34, compared to $0.27 in the year-ago quarter.The reported revenue represents a surprise of +0.9% over the Zacks Consensus Estimate of $61.07 million. With the consensus EPS estimate being $0.33, the EPS surprise was +3.03%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Docebo performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Customers: 3,978 versus the two-analyst average estimate of 4,012.Annual Recurring Revenue: $235.6 million versus $236.89 million estimated by two analysts on average.Revenue- Professional Services: $3.58 million compared to the $2.76 million average estimate based on four analysts. The reported number represents a change of +26.9% year over year.Revenue- Subscription Revenue: $58.05 million versus the four-analyst average estimate of $58.17 million. The reported number represents a year-over-year change of +10.3%.View all Key Company Metrics for Docebo here>>>Shares of Docebo have returned -11.3% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Docebo Inc. (DCBO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks